- With Mayo Clinic psychiatrist
David Mrazek, M.D.
read biographyclose windowBiography of
David Mrazek, M.D.
David Mrazek, M.D.
Dr. David A. Mrazek is chair of the Department of Psychiatry and Psychology at Mayo Clinic, Rochester, Minn., and a professor of psychiatry at College of Medicine, Mayo Clinic. Dr. Mrazek has developed a federally funded psychiatric pharmacogenomics research program and implemented clinical psychiatric pharmacogenomics services at Mayo Clinic.
He has received numerous awards including the Award for Creativity in Psychiatric Education from the American College of Psychiatrists and the Agnes Purcell McGavin Award for Distinguished Career Achievement in Child and Adolescent Psychiatry from the American Psychiatric Association. He currently serves as chairman of the board of the American Board of Psychiatry and Neurology.
Dr. Mrazek has focused his current efforts on using pharmacogenomics testing to improve clinical care. One of his specific goals is to decrease the risks of taking psychiatric medications.
Latest entries
- Depression sometimes shifts to bipolar disorder
Jan. 21, 2012
- Antidepressant use soaring among Americans 12 and over
Dec. 7, 2011
- Transcranial magnetic stimulation offers hope treating depression
Oct. 19, 2011
- New antidepressant offers hope
Sept. 3, 2011
- Sorting out the evidence for antidepressants
July 22, 2011
About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Depression blog
-
Sept. 23, 2009
Smoking cessation medications and depression: Be cautious
By David Mrazek, M.D.
It's well known how difficult it is to quit smoking.
| Need more help? |
|
The FDA has issued an alert regarding the use of varenicline (Chantix) and buproprion (Wellbutrin or Zyban). In some cases, people using these medications have had suicidal thoughts and behaviors. That doesn't mean no one should take them, but you should have a discussion with your health care provider if you're taking them, especially if you've been diagnosed with depression or another mental illness. The FDA has warned that in some cases those with psychiatric conditions, such as depression, had more severe depressive symptoms if they were taking these medications.
If you are taking these medications, your provider should monitor you for any emerging symptoms. Stop taking these medications and contact your provider immediately if you experience agitation, depressed mood or any other significant behavior changes.
26 comments posted